The openFDA drug enforcement database recorded recall D-0556-2026 with a report date of June 10, 2026: Ascend Laboratories, LLC, of Bedminster, New Jersey, is recalling Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg, Rx only, sold in 30-count bottles. The affected product was manufactured by Alkem Laboratories Ltd. in India and distributed in the United States by Ascend Laboratories of Parsippany, New Jersey, under NDC 67877-501-30. One lot is implicated — lot 24123460, expiring October 31, 2027 — but at scale: 15,696 bottles of 30, a meaningful chunk of nationwide supply for this combination.
Unlike the nitrosamine recalls dominating the enforcement feed this month, this is not an impurity story. It is a potency-and-release story. The reason for recall, per the openFDA record, points to a failure of the dissolution test, the standard used to confirm that a tablet releases its active ingredient at the expected rate in the body. When dissolution fails on the low side, patients may absorb less drug than the label promises.
"Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications"— openFDA Drug Enforcement Report D-0556-2026, source
What does a failed dissolution specification actually mean?
Dissolution testing measures how quickly and completely a solid dose releases its active ingredient under controlled laboratory conditions meant to approximate the gut. It is one of the cornerstone release tests every batch must pass before shipment, and it is doubly important for generics: bioequivalence to the reference product is the entire basis on which an abbreviated new drug application is approved. A lot that fails dissolution with olmesartan content below specification means the tablets, when tested, did not release enough of the angiotensin-receptor-blocker component within the required window. In practical terms, a patient relying on the 40 mg olmesartan portion for blood-pressure control could be getting an under-dose.
That is why the recall carries a Class II classification — temporary or medically reversible adverse consequences with a remote probability of serious harm. Uncontrolled hypertension over a sustained period carries real cardiovascular risk, but the failure here is a release-rate problem in a single lot, not a wholesale absence of active ingredient, and prescribers can monitor and adjust. The recall was firm-initiated and voluntary, with initial notification by letter, and its status is listed as ongoing. Distribution was nationwide.
The economics of a release-spec failure in a low-margin generic
For a generics distributor like Ascend, the financial sting of a dissolution failure is different in kind from a nitrosamine event but similar in shape: it lands on a thin-margin product where every step of remediation eats into already-slim economics. The combination of amlodipine, a calcium-channel blocker, and olmesartan medoxomil, an angiotensin-receptor blocker, is a workhorse fixed-dose generic for hypertension — prescribed in volume precisely because it is cheap and combines two mechanisms in one pill. A 15,696-bottle recall of a single strength is large enough to disrupt fill rates at the wholesaler level and to trigger the costs that follow any recall: reverse logistics, destruction or quarantine, investigation of the root cause, and the requalification of the affected manufacturing line at Alkem.
The manufacturing geography is itself a recurring theme in the openFDA stream. The tablets were made in India by Alkem and distributed by a U.S. entity — the same outsourced, multi-party structure that defines most of the American generic supply. When a release test fails, the distributor whose name is on the label initiates the recall, but the corrective action sits with the overseas manufacturer who ran the batch. That separation between the brand that faces the patient and the plant that made the product is a structural feature of the generic economy, and it is one reason quality failures can be slow to surface and slower to resolve.
What the record does and does not tell us
The openFDA entry is precise about the failure mode and the scope. Lot 24123460 failed dissolution; olmesartan content was below specification; 15,696 bottles are affected; distribution was U.S.A. nationwide; the recall was initiated on May 5, 2026, and posted June 10. What it does not say is whether other lots from the same campaign are at risk, what the measured dissolution shortfall actually was, or whether the root cause was a formulation, raw-material, or process problem. Enforcement records are a reliable ledger of actions taken, not a substitute for the firm's own investigation report.
Two practical takeaways for anyone watching the generic combination market. First, dissolution failures are a leading indicator of process control problems at a manufacturing site; a single recall is noise, but a pattern across lots or sites would be a signal worth tracking. Second, the roughly five-week gap between the May 5 initiation and the June 10 public posting is a reminder that the openFDA feed is a trailing data source — useful for understanding the shape of quality risk across the industry, less useful for catching a supply disruption in real time. For now, D-0556-2026 reads as a contained, well-handled release-spec failure on one lot of a common blood-pressure generic, with no reported injuries and a remediation path that runs back to the manufacturing plant in India.
How dissolution failures differ from impurity recalls in the enforcement feed
It is worth situating this recall against the impurity-driven actions that dominate the same June 10 batch. A nitrosamine or contamination recall reflects a problem with what is in the tablet — a foreign or carcinogenic substance that should not be there. A dissolution failure reflects a problem with how the tablet behaves — the right ingredients in the right amounts, released too slowly or incompletely. The two failure modes carry different root-cause investigations and different remediation paths. Impurity problems often trace to the synthesis or storage of the active ingredient and can implicate every lot made the same way; dissolution problems more often trace to the formulation, the tableting process, or a specific raw-material batch, and tend to be more lot-specific. That is consistent with what the Ascend record shows — a single implicated lot rather than a sweeping multi-lot pull. For an analyst reading the feed, the failure mode is a useful first filter on how contained a recall is likely to be, and a dissolution miss on one lot generally signals a narrower problem than an NDSRI finding on a widely used molecule.
theradeals tracks generic-drug quality enforcement as a window into the operating health of the low-margin manufacturers and distributors that supply the bulk of America's prescriptions.